Venetoclax, a bona fide synthetic BH3 mimetic that is a selective inhibitor of the BCL‐2 protein (Souers et al. 2013), is approved for use in several hematologic malignancies, including acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL), either as a monotherapy or in drug combinations (Gibson et al. 2021; Lasica and Anderson 2021). This evidence concerns the gene BCL2 and acute myeloid leukemia.